Benign Prostatic Hypertrophy Treatment Patterns & Outcomes: Marketscan

GlaxoSmithKline35,032 enrolled

Overview

This retrospective study aims to assess treatment patterns within 1 year of initiating BPH treatment, including 5-alpha-reductase inhibitor (5ARI) monotherapy, alpha-blocker (AB) monotherapy, early combination therapy, and delayed combination therapy. The MarketScan database will be utilized for this study (2000-2008)

Study Type

OBSERVATIONAL

Enrollment

35,032

Conditions

Prostatic Hyperplasia

Interventions

5ARIDRUG

Dutasteride or Finasteride

ABDRUG

Doxazosin, Prazosin, Tamsulosin, Terazosin or Alfuzosin

Eligibility

Sex: MALEMin age: 50 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Male * aged 50 years or older * a diagnostic claim for BPH * at least one prescription claim for a 5ARI or AB in the enrollment period * continuous eligibility for 6 months prior to and 12 months after index prescription date Exclusion Criteria: * diagnosis of prostate or bladder cancer during the study period * any prostate-related surgical procedure within 1 month of the index prescription date * prescription claim for finasteride 1 mg for male pattern baldness during the study period

Outcomes

Primary Outcomes

Number of Participants by Treatment Cohort With and Without a Benign Prostatic Hypertrophy (BPH) Diagnosis

The number of participants treated with alpha-blocker (AB) and 5a lpha reductase inhibitor (5ARI) as monotherapy or in combination reported by the presence or absence of a diagnosis code for BPH (International Classification of Disease, Ninth Revision, Clinical Modification codes: 222.2 and 600.xx). Early combination therapy was defined as the addition of 5ARI to existing AB therapy within 30 days of the initial AB pharmacy claim. Delayed combination therapy was defined as the addition of 5ARI to AB therapy after 30 day but within one year of the initial AB pharmacy claim.

Time frame: 4 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.